Biotech News
Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update
~1.35 million total VOQUEZNA ® prescriptions filled to date $58.3 million in Q1 net revenues, a 104% increase year-over-year Q1 operating expenses of $61.8 million; non-GAAP operating expenses of $56.2 million and net cash usage of ~$15 million, reflecting continued expense discipline and